{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:12:53Z","timestamp":1789992773816,"version":"4.0.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The abnormal accumulation of alpha-Synuclein (\u03b1Syn) within neurons is a hallmark of synucleinopathies, such as Parkinson's disease (PD), and could stem from impaired protein degradation. Genetic, in vitro, and\n                    <jats:italic>post-mortem<\/jats:italic>\n                    studies have suggested that lysosomal dysfunction and impaired proteolytic activity play important roles in the pathogenesis of PD. Lysosomes have been proposed as key sites for \u03b1Syn degradation, but direct evidence of the lysosomal localization of endogenous \u03b1Syn in the human brain is limited. This study aimed to investigate the localization of \u03b1Syn proteoforms, including different post-translational modifications (PTMs), within lysosomes of\n                    <jats:italic>post-mortem<\/jats:italic>\n                    human nigral neurons. We analyzed formalin-fixed, paraffin-embedded brain tissue from donors diagnosed with PD, PD with Dementia (PDD) or incidental Lewy body disease (iLBD).\n                    <jats:italic>Substantia nigra<\/jats:italic>\n                    sections were assessed using an extensive panel of \u03b1Syn-specific antibodies, including PTM-specific antibodies, and selected lysosomal markers via multiplex immunofluorescence, confocal and stimulated emission depletion\u00a0(STED)\u00a0microscopy. Here, we demonstrate widespread accumulation of \u03b1Syn within lysosomes in nigral dopaminergic neuron somas of donors with PD\/PDD and iLBD. This lysosomal \u03b1Syn appeared morphologically distinct from cytosolic inclusions such as Lewy bodies (LBs) and related macro-aggregates, and was present both in cells with and without these larger \u03b1Syn deposits. When present, macro-aggregates were consistently accompanied by ring-shaped lysosomal structures. Compared to other neuronal morphologies, lysosomal \u03b1Syn was the most frequent morphology at early Braak stages (1\u20134), with a decline at later stages (5\u20136). Interestingly, lysosomal \u03b1Syn was detected solely by targeting the N-terminus or the NAC domain of \u03b1Syn, and not with antibodies targeting Serine 129-phosphorylated \u03b1Syn or other epitopes at the C-terminus (CT), suggesting that lysosome-associated \u03b1Syn lacks the CT. Our findings reveal two co-existing pools of neuronal somatic \u03b1Syn: a CT-negative lysosome-associated form, and a primarily non-lysosomal CT-positive form. Overall, we provide direct evidence of lysosomal involvement in cellular \u03b1Syn metabolism in\n                    <jats:italic>post-mortem<\/jats:italic>\n                    human PD brain.\n                  <\/jats:p>","DOI":"10.1186\/s13024-025-00884-3","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:24Z","timestamp":1761900444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["C-terminus-dependent detection of lysosomal alpha-synuclein in nigral Parkinson\u2019s disease human brain neurons"],"prefix":"10.1186","volume":"20","author":[{"given":"Martino L.","family":"Morella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bana","family":"Al Khayrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim E.","family":"Moors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"in\u2019t Veld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Frigerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Udayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram L.","family":"van der Gaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma D. J.","family":"van de Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"884_CR1","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","volume":"8","author":"L Maroteaux","year":"1988","unstructured":"Maroteaux L, Campanelli JT, Scheller RH. Synuclein - a neuron-specific protein localized to the nucleus and presynaptic nerve-terminal. J Neurosci. 1988;8:2804\u201315.","journal-title":"J Neurosci"},{"key":"884_CR2","doi-asserted-by":"publisher","first-page":"e72286","DOI":"10.1371\/journal.pone.0072286","volume":"8","author":"CA Waudby","year":"2013","unstructured":"Waudby CA, Camilloni C, Fitzpatrick AWP, Cabrita LD, Dobson CM, Vendruscolo M, Christodoulou J. In-cell NMR characterization of the secondary structure populations of a disordered conformation of \u03b1-synuclein within E. coli cells. Plos One. 2013;8:e72286.","journal-title":"Plos One"},{"key":"884_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16:83.","journal-title":"Mol Neurodegener"},{"key":"884_CR4","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1038\/ncomms4827","volume":"5","author":"G Fusco","year":"2014","unstructured":"Fusco G, De Simone A, Gopinath T, Vostrikov V, Vendruscolo M, Dobson CM, Veglia G. Direct observation of the three regions in \u03b1-synuclein that determine its membrane-bound behaviour. Nat Commun. 2014;5:3827.","journal-title":"Nat Commun"},{"key":"884_CR5","doi-asserted-by":"crossref","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.","DOI":"10.1038\/s41419-023-05672-9"},{"key":"884_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2009.03.021","volume":"389","author":"K Vamvaca","year":"2009","unstructured":"Vamvaca K, Volles MJ, Lansbury PT. The first N-terminal amino acids of \u03b1-synuclein are essential for \u03b1-helical structure formation and membrane binding in yeast. J Mol Biol. 2009;389:413\u201324.","journal-title":"J Mol Biol"},{"key":"884_CR7","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.bpj.2010.06.035","volume":"99","author":"T Bartels","year":"2010","unstructured":"Bartels T, Ahlstrom LS, Leftin A, Kamp F, Haass C, Brown MF, Beyer K. The n-terminus of the intrinsically disordered protein \u03b1-synuclein triggers membrane binding and helix folding. Biophys J. 2010;99:2116\u201324.","journal-title":"Biophys J"},{"key":"884_CR8","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1039\/C7CP08321A","volume":"20","author":"L Xu","year":"2018","unstructured":"Xu L, Bhattacharya S, Thompson D. The fold preference and thermodynamic stability of \u03b1-synuclein fibrils is encoded in the non-amyloid-\u03b2 component region. Phys Chem Chem Phys. 2018;20:4502\u201312.","journal-title":"Phys Chem Chem Phys"},{"key":"884_CR9","doi-asserted-by":"publisher","first-page":"22680","DOI":"10.1074\/jbc.M101181200","volume":"276","author":"MS Nielsen","year":"2001","unstructured":"Nielsen MS, Vorum H, Lindersson E, Jensen PH. Ca2+ binding to \u03b1-synuclein regulates ligand binding and oligomerization. J Biol Chem. 2001;276:22680\u20134.","journal-title":"J Biol Chem"},{"key":"884_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","volume":"14","author":"A Iwai","year":"1995","unstructured":"Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer\u2019s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467\u201375.","journal-title":"Neuron"},{"key":"884_CR11","doi-asserted-by":"crossref","unstructured":"Lautenschl\u00e4ger J, Stephens AD, Fusco G, Str\u00f6hl F, Curry N, Zacharopoulou M, Michel CH, Laine R, Nespovitaya N, Fantham M, et al. C-terminal calcium binding of \u03b1-synuclein modulates synaptic vesicle interaction. Nat Commun. 2018;9:712.","DOI":"10.1038\/s41467-018-03111-4"},{"key":"884_CR12","volume-title":"Paralysis agitans","author":"FH Lewy","year":"1912","unstructured":"Lewy FH. Paralysis agitans. I. Pathologische anatomie. Berlin: Springer; 1912."},{"key":"884_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Casta\u00f1o-D\u00edez D, Schweighauser G, Graff-Meyer A, Godie KN, et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019;22:1099\u2013109.","journal-title":"Nat Neurosci."},{"key":"884_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00401-021-02329-9","volume":"142","author":"TE Moors","year":"2021","unstructured":"Moors TE, Maat CA, Niedieker D, Mona D, Petersen D, Timmermans-Huisman E, Kole J, El-Mashtoly SF, Spycher L, Zago W, et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson\u2019s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol. 2021;142:423\u201348.","journal-title":"Acta Neuropathol"},{"key":"884_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fnins.2019.00381","volume":"13","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li X, Li JD. The roles of post-translational modifications on alpha-synuclein in the pathogenesis of Parkinson\u2019s diseases. Front Neurosci. 2019;13:381.","journal-title":"Front Neurosci"},{"key":"884_CR16","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang JP, Kling K, Lee M, et al. Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281:29739\u201352.","journal-title":"J Biol Chem"},{"key":"884_CR17","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/1873-3468.14361","volume":"596","author":"S Huang","year":"2022","unstructured":"Huang S, Mo XL, Wang JY, Ye XY, Yu HJ, Liu YH. \u03b1-Synuclein phase separation and amyloid aggregation are modulated by C-terminal truncations. FEBS Lett. 2022;596:1388\u2013400.","journal-title":"FEBS Lett"},{"key":"884_CR18","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s42003-022-03768-0","volume":"5","author":"C Zhang","year":"2022","unstructured":"Zhang C, Pei YS, Zhang ZT, Xu LL, Liu XL, Jiang L, Pielak GJ, Zhou X, Liu ML, Li CG. C-terminal truncation modulates \u03b1-Synuclein\u2019s cytotoxicity and aggregation by promoting the interactions with membrane and chaperone. Commun Biol. 2022;5:798.","journal-title":"Commun Biol"},{"key":"884_CR19","doi-asserted-by":"crossref","unstructured":"Suthar SK, Lee SY. Truncation or proteolysis of alpha-synuclein in Parkinsonism. Ageing Res Rev. 2023;90:101978.","DOI":"10.1016\/j.arr.2023.101978"},{"key":"884_CR20","doi-asserted-by":"publisher","first-page":"18914","DOI":"10.1074\/jbc.RA118.005603","volume":"293","author":"ZA Sorrentino","year":"2018","unstructured":"Sorrentino ZA, Vijayaraghavan N, Gorion KM, Riffe CJ, Strang KH, Caldwell J, Giasson BI. Physiological C-terminal truncation of \u03b1-synuclein potentiates the prion-like formation of pathological inclusions. J Biol Chem. 2018;293:18914\u201332.","journal-title":"J Biol Chem"},{"key":"884_CR21","doi-asserted-by":"crossref","unstructured":"Kellie JF, Higgs RE, Ryder JW, Major A, Beach TG, Adler CH, Merchant K, Knierman MD. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson\u2019s disease brain tissue by intact protein mass spectrometry. Sci Rep. 2014;4:5797.","DOI":"10.1038\/srep05797"},{"key":"884_CR22","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1073\/pnas.0406976102","volume":"102","author":"WX Li","year":"2005","unstructured":"Li WX, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, J\u00e4k\u00e4l\u00e4 P, Hartmann T, Price DL, Lee MK. Aggregation promoting C-terminal truncation of \u03b1-synuclein is a normal cellular process and is enhanced by the familial Parkinson\u2019s disease-linked mutations. P Natl Acad Sci USA. 2005;102:2162\u20137.","journal-title":"P Natl Acad Sci USA"},{"key":"884_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134.","journal-title":"Nat Cell Biol"},{"key":"884_CR24","doi-asserted-by":"crossref","unstructured":"Moors TE, Mona D, Luehe S, Duran-Pacheco G, Spycher L, Mundigl O, Kaluza K, Huber S, Hug MN, Kremer T, et al. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol Commun. 2022;10:82","DOI":"10.1186\/s40478-022-01382-z"},{"key":"884_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuroscience.2011.10.042","volume":"200","author":"G Muntane","year":"2012","unstructured":"Muntane G, Ferrer I, Martinez-Vicente M. Alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience. 2012;200:106\u201319.","journal-title":"Neuroscience"},{"key":"884_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00401-008-0409-8","volume":"116","author":"TG Beach","year":"2008","unstructured":"Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, et al. Evaluation of \u03b1-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008;116:277\u201388.","journal-title":"Acta Neuropathol"},{"key":"884_CR27","doi-asserted-by":"crossref","unstructured":"Drobny A, Dobert J, Kluge A, Bunk J, Schlothauer T, Zunke F, Huarcaya SP. The role of lysosomal cathepsins in neurodegeneration: mechanistic insights, diagnostic potential and therapeutic approaches. Biochim Biophys Acta Mol Cell Res. 2022;1869:119243.","DOI":"10.1016\/j.bbamcr.2022.119243"},{"key":"884_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1523\/JNEUROSCI.3809-03.2004","volume":"24","author":"HJ Lee","year":"2004","unstructured":"Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of \u03b1-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004;24:1888\u201396.","journal-title":"J Neurosci"},{"key":"884_CR29","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292\u20135.","journal-title":"Science"},{"key":"884_CR30","doi-asserted-by":"publisher","first-page":"13621","DOI":"10.1074\/jbc.M109.074617","volume":"285","author":"SK Mak","year":"2010","unstructured":"Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem. 2010;285:13621\u20139.","journal-title":"J Biol Chem"},{"key":"884_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-023-00614-w","volume":"10","author":"JA Wiseman","year":"2024","unstructured":"Wiseman JA, Murray HC, Faull R, Dragunow M, Turner CP, Dieriks BV, Curtis MA. Aggregate-prone brain regions in Parkinson\u2019s disease are rich in unique N-terminus alpha-synuclein conformers with high proteolysis susceptibility. NPJ Parkinsons Dis. 2024;10:1.","journal-title":"NPJ Parkinsons Dis"},{"key":"884_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029460","volume":"6","author":"T Hasegawa","year":"2011","unstructured":"Hasegawa T, Konno M, Baba T, Sugeno N, Kikuchi A, Kobayashi M, Miura E, Tanaka N, Tamai K, Furukawa K, et al. The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of alpha-synuclein. PLoS ONE. 2011;6: e29460.","journal-title":"PLoS ONE"},{"key":"884_CR33","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.15252\/embj.201593411","volume":"35","author":"S Abounit","year":"2016","unstructured":"Abounit S, Bousset L, Loria F, Zhu S, de Chaumont F, Pieri L, Olivo-Marin JC, Melki R, Zurzolo C. Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. Embo J. 2016;35:2120\u201338.","journal-title":"Embo J"},{"key":"884_CR34","doi-asserted-by":"crossref","unstructured":"Senol AD, Samarani M, Syan S, Guardia CM, Nonaka T, Liv N, Latour-Lambert P, Hasegawa M, Klumperman J, Bonifacino JS, Zurzolo C. \u0391-synuclein fibrils subvert lysosome structure and function for the propagation of protein misfolding between cells through tunneling nanotubes. PLoS Biol. 2021;19:e3001287.","DOI":"10.1371\/journal.pbio.3001287"},{"key":"884_CR35","doi-asserted-by":"publisher","first-page":"23542","DOI":"10.1074\/jbc.M801992200","volume":"283","author":"T Vogiatzi","year":"2008","unstructured":"Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type \u03b1-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283:23542\u201356.","journal-title":"J Biol Chem"},{"key":"884_CR36","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1093\/brain\/awt131","volume":"136","author":"M Xilouri","year":"2013","unstructured":"Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L. Boosting chaperone-mediated autophagy mitigates \u03b1-synuclein-induced neurodegeneration. Brain. 2013;136:2130\u201346.","journal-title":"Brain"},{"key":"884_CR37","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.neuron.2019.09.001","volume":"104","author":"LK Cuddy","year":"2019","unstructured":"Cuddy LK, Wani WY, Morella ML, Pitcairn C, Tsutsumi K, Fredriksen K, Justman CJ, Grammatopoulos TN, Belur NR, Zunke F, et al. Stress-induced cellular clearance is mediated by the SNARE protein ykt6 and disrupted by \u03b1-synuclein. Neuron. 2019;104:869.","journal-title":"Neuron"},{"key":"884_CR38","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.1520335113","volume":"113","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. \u03b1-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. P Natl Acad Sci USA. 2016;113:1931\u20136.","journal-title":"P Natl Acad Sci USA"},{"key":"884_CR39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.nbd.2018.02.019","volume":"114","author":"G Puska","year":"2018","unstructured":"Puska G, Lutz MI, Molnar K, Regelsberger G, Ricken G, Pirker W, Laszlo L, Kovacs GG. Lysosomal response in relation to \u03b1-synuclein pathology differs between Parkinson\u2019s disease and multiple system atrophy. Neurobiol Dis. 2018;114:140\u201352.","journal-title":"Neurobiol Dis"},{"key":"884_CR40","unstructured":"Ethical and legal declaration of the Netherlands Brain Bank.\u00a0https:\/\/www.brainbank.nl\/media\/uploads\/file\/Ethical%20declaration%202019.pdf."},{"key":"884_CR41","unstructured":"BrainNet Europe Consortium - Code of Conduct.\u00a0https:\/\/www.brainbank.nl\/media\/uploads\/file\/Code-of-conduct.pdf."},{"key":"884_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00401-009-0523-2","volume":"117","author":"I Alafuzoff","year":"2009","unstructured":"Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, et al. Staging\/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe consortium. Acta Neuropathol. 2009;117:635\u201352.","journal-title":"Acta Neuropathol"},{"key":"884_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National institute on aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"884_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40478-022-01468-8","volume":"10","author":"MF Altay","year":"2022","unstructured":"Altay MF, Liu AKL, Holton JL, Parkkinen L, Lashuel HA. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders. Acta Neuropathol Commun. 2022;10:163.","journal-title":"Acta Neuropathol Commun"},{"key":"884_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41531-023-00604-y","volume":"9","author":"MF Altay","year":"2023","unstructured":"Altay MF, Kumar ST, Burtscher J, Jagannath S, Strand C, Miki Y, Parkkinen L, Holton JL, Lashuel HA. Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases. Npj Parkinsons Dis. 2023;9:161.","journal-title":"Npj Parkinsons Dis"},{"key":"884_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00401-012-0964-x","volume":"124","author":"GG Kovacs","year":"2012","unstructured":"Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, Leisser I, Verchere J, Baron T, Alafuzoff I, et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012;124:37\u201350.","journal-title":"Acta Neuropathol"},{"key":"884_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0304-3940(03)00781-X","volume":"349","author":"RJ Perrin","year":"2003","unstructured":"Perrin RJ, Payton JE, Barnett DH, Wraight CL, Woods WS, Ye L, George JM. Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett. 2003;349:133\u20135.","journal-title":"Neurosci Lett"},{"key":"884_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0304-3940(99)00411-5","volume":"269","author":"R Jakes","year":"1999","unstructured":"Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, Goedert M. Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett. 1999;269:13\u20136.","journal-title":"Neurosci Lett"},{"key":"884_CR49","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","volume":"34","author":"D Games","year":"2014","unstructured":"Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, et al. Reducing c-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models. J Neurosci. 2014;34:9441\u201354.","journal-title":"J Neurosci"},{"key":"884_CR50","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","volume":"182","author":"D Games","year":"2013","unstructured":"Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, et al. Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal truncated \u03b1-synuclein. Am J Pathol. 2013;182:940\u201353.","journal-title":"Am J Pathol"},{"key":"884_CR51","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/cne.24468","volume":"526","author":"V Delic","year":"2018","unstructured":"Delic V, Chandra S, Abdelmotilib H, Maltbie T, Wang S, Kem D, Scott HJ, Underwood RN, Liu Z, Volpicelli-Daley LA, West AB. Sensitivity and specificity of phospho-Ser129 alpha-synuclein monoclonal antibodies. J Comp Neurol. 2018;526:1978\u201390.","journal-title":"J Comp Neurol"},{"key":"884_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41531-022-00388-7","volume":"8","author":"HA Lashuel","year":"2022","unstructured":"Lashuel HA, Mahul-Mellier AL, Novello S, Hegde RN, Jasiqi Y, Altay MF, Donzelli S, DeGuire SM, Burai R, Magalhaes P, et al. Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity. NPJ Parkinsons Dis. 2022;8:136.","journal-title":"NPJ Parkinsons Dis"},{"key":"884_CR53","doi-asserted-by":"crossref","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, Mcart DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","DOI":"10.1038\/s41598-017-17204-5"},{"key":"884_CR54","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"884_CR55","unstructured":"Posit Team. RStudio: Integrated Development Environment for R. Posit Software, PBC; 2025."},{"key":"884_CR56","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2021."},{"key":"884_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02707-z","volume":"147","author":"TE Moors","year":"2024","unstructured":"Moors TE, Morella ML, Bertran-Cobo C, Geut H, Udayar V, Timmermans-Huisman E, Ingrassia AMT, Breve JJP, Bol J, Bonifati V, et al. Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases. Acta Neuropathol. 2024;147: 67.","journal-title":"Acta Neuropathol"},{"key":"884_CR58","doi-asserted-by":"crossref","unstructured":"Mahul-Mellier A-L, Altay MF, Maharjan N, et al. Differential role of C-terminal\u00a0truncations on alpha-synuclein pathology and Lewy body formation. npj Parkinsons\u00a0Dis. 2025;11:261.","DOI":"10.1038\/s41531-025-01084-y"},{"key":"884_CR59","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1016\/j.cell.2021.09.007","volume":"184","author":"H Scheiblich","year":"2021","unstructured":"Scheiblich H, Dansokho C, Mercan D, Schmidt SV, Bousset L, Wischhof L, Eikens F, Odainic A, Spitzer J, Griep A, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184:5089.","journal-title":"Cell"},{"key":"884_CR60","doi-asserted-by":"crossref","unstructured":"Li Y, Li P, Li R, Xu Q. Intracellular antibody delivery mediated by lipids, polymers, and inorganic nanomaterials for therapeutic applications. Adv Ther. 2020;3:2000178.","DOI":"10.1002\/adtp.202000178"},{"key":"884_CR61","doi-asserted-by":"crossref","unstructured":"Gaston J, Maestrali N, Lalle G, Gagnaire M, Masiero A, Dumas B, Dabdoubi T, Radosevic K, Berne PF. Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions.\u00a0Sci Rep. 2019;9:18688.","DOI":"10.1038\/s41598-019-55091-0"},{"key":"884_CR62","doi-asserted-by":"crossref","unstructured":"Abraham A, Natraj U, Karande AA, Gulati A, Murthy MRN, Murugesan S, Mukunda P, Savithri HS. Intracellular delivery of antibodies by chimeric Sesbania mosaic virus (SeMV) virus like particles. Sci Rep. 2016;6:21803.","DOI":"10.1038\/srep21803"},{"key":"884_CR63","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/pnas.1500937112","volume":"112","author":"RP McGlinchey","year":"2015","unstructured":"McGlinchey RP, Lee JC. Cysteine cathepsins are essential in lysosomal degradation of \u03b1-synuclein. P Natl Acad Sci USA. 2015;112:9322\u20137.","journal-title":"P Natl Acad Sci USA"},{"key":"884_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tins.2021.12.004","volume":"45","author":"V Udayar","year":"2022","unstructured":"Udayar V, Chen Y, Sidransky E, Jagasia R. Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci. 2022;45:184\u201399.","journal-title":"Trends Neurosci"},{"key":"884_CR65","doi-asserted-by":"publisher","first-page":"167932","DOI":"10.1016\/j.jmb.2022.167932","volume":"435","author":"R M\u00e4chtel","year":"2023","unstructured":"M\u00e4chtel R, Boros FA, Dobert JP, Arnold P, Zunke F. From lysosomal storage disorders to Parkinson\u2019s disease-challenges and opportunities. J Mol Biol. 2023;435:167932.","journal-title":"J Mol Biol"},{"key":"884_CR66","doi-asserted-by":"crossref","unstructured":"Gehrlein A, Udayar V, Anastasi N, Morella ML, Ruf I, Brugger D, von der Mark S, Thoma R, Rufer A, Heer D, et al. Targeting neuronal lysosomal dysfunction caused by \u03b2-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat Commun. 2023;14:2057.","DOI":"10.1038\/s41467-023-37632-4"},{"key":"884_CR67","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1002\/mds.28112","volume":"35","author":"J den Heijer","year":"2020","unstructured":"den Heijer J, Cullen V, Quadri M, Schmitz A, Hilt D, Lansbury P, Berendse H, de Berg W, de Bie R, Boertien J, et al. A large-scale full GBA1 gene screening in Parkinson\u2019s disease in the Netherlands: 18 novel and 1 \u201cDutch\u201d variant. Movement Disord. 2020;35:S197\u20138.","journal-title":"Movement Disord"},{"key":"884_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ana.20186","volume":"56","author":"KS McNaught","year":"2004","unstructured":"McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson\u2019s disease. Ann Neurol. 2004;56:149\u201362.","journal-title":"Ann Neurol"},{"key":"884_CR69","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbrc.2008.05.045","volume":"372","author":"HJ Lee","year":"2008","unstructured":"Lee HJ, Suk JE, Bae EJ, Lee SJ. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun. 2008;372:423\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"884_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41419-021-03441-0","volume":"12","author":"M Bi","year":"2021","unstructured":"Bi M, Du X, Jiao Q, Chen X, Jiang H. Expanding the role of proteasome homeostasis in Parkinson\u2019s disease: beyond protein breakdown. Cell Death Dis. 2021;12:154.","journal-title":"Cell Death Dis"},{"key":"884_CR71","doi-asserted-by":"publisher","first-page":"10224","DOI":"10.1074\/jbc.REV120.011743","volume":"295","author":"ZA Sorrentino","year":"2020","unstructured":"Sorrentino ZA, Giasson BI. The emerging role of alpha-synuclein truncation in aggregation and disease. J Biol Chem. 2020;295:10224\u201344.","journal-title":"J Biol Chem"},{"key":"884_CR72","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nsmb.3433","volume":"24","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Kang SS, Liu X, Ahn EH, Zhang Z, He L, Iuvone PM, Duong DM, Seyfried NT, Benskey MJ, et al. Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson\u2019s disease. Nat Struct Mol Biol. 2017;24:632\u201342.","journal-title":"Nat Struct Mol Biol"},{"key":"884_CR73","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41422-019-0241-9","volume":"30","author":"EH Ahn","year":"2020","unstructured":"Ahn EH, Kang SS, Liu X, Chen G, Zhang Z, Chandrasekharan B, Alam AM, Neish AS, Cao X, Ye K. Initiation of Parkinson\u2019s disease from gut to brain by delta-secretase. Cell Res. 2020;30:70\u201387.","journal-title":"Cell Res"},{"key":"884_CR74","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2990.2004.00572.x","volume":"30","author":"K Beyer","year":"2004","unstructured":"Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, Ferrer I, Ariza A. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol. 2004;30:601\u20137.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"884_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10048-007-0106-0","volume":"9","author":"K Beyer","year":"2008","unstructured":"Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I, Ariza A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics. 2008;9:15\u201323.","journal-title":"Neurogenetics"},{"key":"884_CR76","doi-asserted-by":"crossref","unstructured":"Quintin S, Lloyd GM, Paterno G, Xia YX, Sorrentino Z, Bell BM, Gorion KM, Lee EB, Prokop S, Giasson BI. Cellular processing of \u03b1-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114. J Biol Chem. 2023;299:104912.","DOI":"10.1016\/j.jbc.2023.104912"},{"key":"884_CR77","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI200215777","volume":"110","author":"M Neumann","year":"2002","unstructured":"Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest. 2002;110:1429\u201339.","journal-title":"J Clin Invest"},{"key":"884_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01785-0","volume":"12","author":"SG Choi","year":"2024","unstructured":"Choi SG, Tittle T, Garcia-Prada D, Kordower JH, Melki R, Killinger BA. Alpha-synuclein aggregates are phosphatase resistant. Acta Neuropathol Commun. 2024;12: 84.","journal-title":"Acta Neuropathol Commun"},{"key":"884_CR79","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1038\/s41467-024-46832-5","volume":"15","author":"DD Dhavale","year":"2024","unstructured":"Dhavale DD, Barclay AM, Borcik CG, Basore K, Berthold DA, Gordon IR, Liu J, Milchberg MH, O\u2019Shea JY, Rau MJ, et al. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. Nat Commun. 2024;15:2750.","journal-title":"Nat Commun"},{"key":"884_CR80","doi-asserted-by":"crossref","unstructured":"Fan Y, Sun Y, Yu W, Tao Y, Xia W, Liu Y, Zhao Q, Tang Y, Sun Y, Liu F, et al. Conformational change of alpha-synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson\u2019s disease.\u00a0Structure. 2023;31:78\u201387.e5.","DOI":"10.1016\/j.str.2022.11.013"},{"key":"884_CR81","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41422-018-0075-x","volume":"28","author":"Y Li","year":"2018","unstructured":"Li Y, Zhao C, Luo F, Liu Z, Gui X, Luo Z, Zhang X, Li D, Liu C, Li X. Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy. Cell Res. 2018;28:897\u2013903.","journal-title":"Cell Res"},{"key":"884_CR82","doi-asserted-by":"crossref","unstructured":"Frey L, Ghosh D, Qureshi BM, Rhyner D, Guerrero-Ferreira R, Pokharna A, Kwiatkowski W, Serdiuk T, Picotti P, Riek R, Greenwald J. On the pH-dependence of \u03b1-synuclein amyloid polymorphism and the role of secondary nucleation in seed-based amyloid propagation. Elife. 2024;12:RP93562.","DOI":"10.7554\/eLife.93562.4"},{"key":"884_CR83","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/B978-0-444-63639-3.00005-0","volume":"150","author":"NM Klioueva","year":"2018","unstructured":"Klioueva NM, Rademaker MC, Huitinga I. Design of a European code of conduct for brain banking. Handb Clin Neurol. 2018;150:51\u201381.","journal-title":"Handb Clin Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00884-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:03:22Z","timestamp":1761905002000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00884-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00884-3","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Post-mortem\n                      human brain tissue was collected from clinically diagnosed and neuropathologically verified donors with PD, PDD, iLBD, and non-demented controls by the Netherlands Brain Bank (NBB,\n                      \n                      ). Informed consent for brain autopsy and the use of brain tissue and clinical information for scientific research was obtained from either the donor or their next of kin, in accordance with all local ethical and legal guidelines. The NBB's Code of Conduct and Ethical Declaration\u00a0is publicly accessible to ensure compliance with these standards [\n                      \n                      ,\n                      \n                      ,\n                      \n                      ]. All procedures were approved by the Institutional Review Board and Medical Ethical Board (METC) of the VU University Medical Center (VUmc), Amsterdam.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests. M.L.M., T.E.M.,\u00a0and V.U. are or were full-time employees of Roche\/F. Hoffmann-La Roche Ltd., and may additionally hold Roche stock\/stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}